A Phase 3, Randomized, Open-Label, Multicenter, Global Study of Durvalumab and Bacillus Calmette-Guérin (BCG) vs BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer (NMIBC) Patients (POTOMAC)
Tabs
Speciality:
Oncology (medical)
Keywords:
durvalumab, BCG, NMIBC, PD-L1 inhibitor, immunotherapy